Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
NCT ID: NCT01478737
Last Updated: 2024-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2011-11-30
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ozurdex in Reducing PVR After Vitreotomy in PDR
NCT05415826
Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)
NCT01613716
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
NCT01571232
Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections
NCT06894017
Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.
NCT02121197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sham
Vitrectomy only
Vitrectomy
Vitrectomy only
Intravitreal Ozurdex
Intravitreal Ozurdex after vitrectomy
Intravitreal dexamethasone implant
Intravitreal Ozurdex after vitrectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal dexamethasone implant
Intravitreal Ozurdex after vitrectomy
Vitrectomy
Vitrectomy only
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Vitreous hemorrhage of non-PDRP origin
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anders Kvanta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anders Kvanta
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anders Kvanta, PhD
Role: PRINCIPAL_INVESTIGATOR
St. Erik Eye Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Erik Eye Hospital
Stockholm, NonUS, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PDRPOZU1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.